XBiotech, Inc. (XBIT)

[TheFinalCD]

BIOTECH STOCKS WORTH CHASING: XBIOTECH, INC. (XBIT), ELEVEN BIOTHERAPEUTICS, INC. (EBIO)

XBiotech, Inc. (XBIT) ended last trading session with a change of 19.02 percent. It trades at an average volume of 198.66K shares versus 1.07M shares recorded at the end of last trading session. The share price of $24.9 is at a distance of 291.51 percent from its 52-week low and down 14.22 percent versus its peak. The company has a market cap of $676.78M and currently has 27.18M shares outstanding. The share price is currently 42.66 percent versus its SMA20, 64.26 percent versus its SMA50, and 104.68 percent versus its SMA200. The stock has a weekly performance of 37.11 percent and is 129.07 percent year-to-date as of the recent close.

On July 02, 2016 XBiotech Inc. (XBIT) presented positive results from a pivotal Phase III trial of Xilonix™, the company’s lead monoclonal (IgG1k) antibody immunotherapy for the treatment of advanced colorectal cancer (CRC). In the study, Xilonix-treated patients with advanced disease and multiple symptoms known to inversely correlate with overall survival experienced a 76% relative increase in clinical response rate (CRR), a novel measure of anti-cancer activity, after 8 weeks of therapy compared to placebo (33% vs. 19%, respectively; p=.0045). In addition, clinical response correlated with improved overall survival. Among responders (in both treatment and placebo arms), clinical response was associated with a 2.7-fold increase in overall survival (11.5 versus 4.2 months in responders vs. non-responders, respectively). Overall survival was not compared between treatment arms because after 8 weeks, all patients were eligible to receive study drug. Treatment with Xilonix was well tolerated, with an adverse event profile comparable to placebo. The data were presented at the 18th European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer in Barcelona, Spain.

Eleven Biotherapeutics, Inc. (EBIO) recently recorded 12.57 percent change and currently at $1.88 is 649 percent away from its 52-week low and down -76.5 percent versus its peak. It has a past 5-day performance of -12.15 percent and trades at an average volume of 3.38M shares. The stock has a 1-month performance of 5.62 percent and is -37.54 percent year-to-date as of the recent close. There were about 19.64M shares outstanding which made its market cap $36.92M. The share price is currently -10.05 percent versus its SMA20, 25.55 percent versus its SMA50, and 12.08 percent versus its SMA200.

On June 13, 2016 Eleven Biotherapeutics, Inc. (EBIO) announced that it has entered into an exclusive license agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (Roche) relating to Eleven’s Interleukin-6 (IL-6) technology. Under the terms of the agreement, Eleven has agreed to grant an exclusive, worldwide license to Roche to develop and commercialize EBI-031, a humanized monoclonal antibody that potently binds IL-6 and inhibits all known forms of IL-6 cytokine signaling, currently being developed for the potential treatment of ocular diseases, and all other IL-6 antagonist antibody technology owned by Eleven.

Under the agreement, Eleven will be entitled to an upfront payment of $7.5 million, along with potential future milestone payments of up to $262.5 million. The first potential future milestone payment is subject to the effectiveness of an investigational new drug application (IND) for EBI-031. This first milestone payment will equal $22.5 million if the IND becomes effective on or before September 15, 2016 or $20.0 million if the IND becomes effective after September 15, 2016. In addition, Eleven could be entitled to receive royalties for net sales of potential future products containing EBI-031 or any other potential future products containing other Eleven IL-6 compounds. Effectiveness of the license agreement is subject to approval of the license by holders of at least a majority of the outstanding shares of Eleven’s common stock.

http://www.zergwatch.com/2016/07/05/biotech-stocks-worth-chasing-xbiotech-inc-xbit-eleven-biotherapeutics-inc-ebio/